公开(公告)号：US20210163483A1

公开(公告)日：2021-06-03

申请号：US17165736

申请日：2021-02-02

Applicant: Teon Therapeutics, Inc.

Inventor： Jiwen Liu ,  Elfatih Elzein

IPC: C07D473/06 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.

公开(公告)号：US11957689B2

公开(公告)日：2024-04-16

申请号：US17960625

申请日：2022-10-05

Applicant: Teon Therapeutics, Inc.

Inventor： Elfatih Elzein ,  Jiwen Liu

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5386 ,  A61K39/395 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5386 ,  A61K39/3955 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

公开(公告)号：US20230143502A1

公开(公告)日：2023-05-11

申请号：US17960625

申请日：2022-10-05

Applicant: Teon Therapeutics, Inc.

Inventor： Elfatih Elzein ,  Jiwen Liu

IPC: A61K31/5377 ,  C07D471/04 ,  C07D519/00 ,  A61K39/395 ,  A61K31/4375 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/5386 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/444

CPC classification number: A61K31/5377 ,  C07D471/04 ,  C07D519/00 ,  A61K39/3955 ,  A61K31/4375 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/5386 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K31/444

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

公开(公告)号：US20230024108A1

公开(公告)日：2023-01-26

申请号：US17626075

申请日：2020-07-15

Applicant: Teon Therapeutics, Inc.

Inventor： Elfatih Elzein ,  Jiwen Liu

IPC: A61K31/519 ,  C07D487/14 ,  C07D519/00 ,  A61K31/551 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the A2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A2A adenosine receptor, such as cancer, with A2A adenosine receptor antagonists.

公开(公告)号：US20240252504A1

公开(公告)日：2024-08-01

申请号：US18596553

申请日：2024-03-05

Applicant: Teon Therapeutics, Inc.

Inventor： Elfatih Elzein ,  Jiwen Liu

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5386 ,  A61K39/395 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5386 ,  A61K39/3955 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

公开(公告)号：US20230192704A1

公开(公告)日：2023-06-22

申请号：US17926347

申请日：2021-05-20

Applicant: Teon Therapeutics, Inc.

Inventor： Jiwen Liu

IPC: C07D487/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00 ,  A61P35/00

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the monocarboxylic acid transporter 4 (MCT4) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of monocarboxylic acid transporter 4 (MCT4) or that we benefit from modulating the monocarboxylic acid transporter 4 (MCT4).

公开(公告)号：US11564928B1

公开(公告)日：2023-01-31

申请号：US17691991

申请日：2022-03-10

Applicant: Teon Therapeutics, Inc.

Inventor： Elfatih Elzein ,  Jiwen Liu

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/5377 ,  A61K31/4375 ,  A61K39/395 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/5386 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/444

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

公开(公告)号：US20220324803A1

公开(公告)日：2022-10-13

申请号：US17615821

申请日：2020-06-09

Applicant: Teon Therapeutics, Inc.

Inventor： Jiwen Liu

IPC: C07D209/42 ,  C07D231/56 ,  C07D471/04 ,  C07D401/06 ,  A61K45/06

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the prostaglandin E2 receptor 4 (EP4) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the action of prostaglandin E2 (PGE2) at the prostaglandin E2 receptor 4 (EP4), such as cancer, with EP4 antagonists.

公开(公告)号：US20220056033A1

公开(公告)日：2022-02-24

申请号：US17391245

申请日：2021-08-02

Applicant: Teon Therapeutics, Inc.

Inventor： Jiwen Liu ,  Elfatih Elzein

IPC: C07D473/06 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.

公开(公告)号：US11124515B2

公开(公告)日：2021-09-21

申请号：US17165736

申请日：2021-02-02

Applicant: Teon Therapeutics, Inc.

Inventor： Jiwen Liu ,  Elfatih Elzein

IPC: C07D473/06 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Disclosed herein are compounds of Formula (III), compositions and formulations thereof, and methods for modulating the A22B adenosine receptor for treatment of A2B adenosine receptor mediated diseases or conditions.